Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT03992339 is registered in ClinicalTrials.gov with Antengene Corporation as lead sponsor.

NCT NCT03992339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03992339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Lead sponsor
Antengene Corporation
Phase
Phase 2
Overall status
Completed
Start date
April 9, 2020
Completion date
December 1, 2023
Enrollment
60 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory diffuse large b-cell lymphoma (dlbcl)